India looks to diplomats to salvage R&D rep; Parexel updates its eClinical offering;

> Ongoing global scrutiny tied to Indian CROs and CMOs is hampering the nation's effort to become a go-to outlet for biopharma R&D, and now the country's diplomats are working to improve the domestic industry's reputation around the world. Story

> Parexel ($PRXL) has updated its eClinical technology, Perceptive MyTrials, to include a mobile-friendly platform that allows sponsors to monitor predictive data analytics for multiple studies at the same time. More

> An independent lab network has bought into the CRO industry, paying an undisclosed sum for Analytical Bio-Chemistry Laboratories. News

Suggested Articles

Dr. Ian Hudson is stepping down after six years in charge of the Medicines and Healthcare products Regulatory Agency next month.

Oncology tests in the U.S. are still failing to adequately represent racial diversity, and more needs to be done to help combat this disparity.

Symphony Health has inked a new deal with Close-Up International aimed at boosting its global data services.